CTOs on the Move

TrueCore Behavioral Solutions

www.truecorebehavioral.com

 
Tampa, Florida-based TrueCore Behavioral Solutions operates residential facilities for youth who have been ordered by the court into juvenile justice facilities. The company has a 20-year history of providing services to at-risk youth, helping young people discover their true core potential to lead productive and rewarding lives. Today, nearly 2,000 TrueCore professionals and staff in facilities across four states offer vital services and support, including alternative education schools and programs for vocational training, substance abuse recovery, behavioral and mental health, and sexual offender treatment.
  • Number of Employees: 1K-5K
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

NP Medical Inc

NP Medical Inc is a Clinton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Star Multi Care Services

Star Multi Care Services is a Melville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Us Health Connect

Us Health Connect is a Fort Washington, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Highline Wellness

Were on a mission to make a more pleasant world, one dose at a time. We provide natural, affordable, and effective CBD supplements to give everyone access to a happier, healthier, and more peaceful state of mind and body. Free 2-Day shipping, Lab Test...

Enterin Inc.

Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.